European CHMP negative opinion of license extension of fluticasone furoate / umeclidinium / vilanterol (Elebrato Ellipta; Temybric Ellipta; Trelegy Ellipta) as maintenance therapy

The manufacturers supporting data did not clearly show that the combination product was effective as maintenance therapy at reducing asthma attacks or controlling symptoms.

Source:

European Medicines Agency